Victory Capital Management Inc. raised its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 81.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 249,611 shares of the medical equipment provider’s stock after purchasing an additional 111,842 shares during the quarter. Victory Capital Management Inc.’s holdings in Zimmer Biomet were worth $30,120,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Longview Partners Guernsey LTD grew its stake in Zimmer Biomet by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after purchasing an additional 1,128,973 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Zimmer Biomet by 7.3% in the third quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock valued at $617,961,000 after buying an additional 357,302 shares during the last quarter. Jana Partners LLC lifted its position in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after buying an additional 662,497 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Zimmer Biomet by 8.1% in the third quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock valued at $487,721,000 after buying an additional 311,654 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Zimmer Biomet by 24.4% in the third quarter. Bank of New York Mellon Corp now owns 2,759,704 shares of the medical equipment provider’s stock valued at $323,134,000 after buying an additional 541,102 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

A number of research firms have recently issued reports on ZBH. Robert W. Baird reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Monday, February 5th. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and raised their price objective for the company from $120.00 to $168.00 in a research report on Wednesday, January 31st. BMO Capital Markets reaffirmed a “buy” rating and issued a $144.00 price objective on shares of Zimmer Biomet in a research report on Tuesday, January 30th. Finally, Leerink Swann raised their price objective on Zimmer Biomet from $142.00 to $146.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $141.67.

Shares of Zimmer Biomet Holdings Inc (NYSE ZBH) opened at $116.39 on Friday. The firm has a market capitalization of $23,740.00, a P/E ratio of 12.90, a P/E/G ratio of 2.03 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.83 and a current ratio of 1.52. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. The business had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm posted $2.14 EPS. analysts predict that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet’s payout ratio is currently 10.64%.

ILLEGAL ACTIVITY WARNING: This story was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://theolympiareport.com/2018/02/11/victory-capital-management-inc-has-30-12-million-holdings-in-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.